Quick Answer
Tenaya Therapeutics, Inc. reported Stockholders Equity of $123.27 million for the year ending 2025.
- Tenaya Therapeutics, Inc. showed an increase of +32.8% in Stockholders Equity from 2024 to 2025.
- This data is from Tenaya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$52.62 million | Q2 2020: -$61.15 million | Q3 2020: -$71.23 million | Q1 2021: -$93.94 million | Q2 2021: -$108.54 million | Q3 2021: $303.70 million | Q1 2022: $249.10 million | Q2 2022: $223.87 million | Q3 2022: $196.33 million | Q1 2023: $215.41 million | Q2 2023: $189.94 million | Q3 2023: $164.88 million | Q1 2024: $158.18 million | Q2 2024: $134.00 million | Q3 2024: $112.60 million | Q1 2025: $119.40 million | Q2 2025: $99.83 million | Q3 2025: $82.87 million.
- Over the full 7 years of available data (2019 to 2025), Tenaya Therapeutics, Inc.'s Stockholders Equity has grown by 381.8%.
- Historical annual values: Fiscal year 2025: $123.27 million | Fiscal year 2024: $92.85 million | Fiscal year 2023: $139.42 million | Fiscal year 2022: $243.38 million | Fiscal year 2021: $278.53 million | Fiscal year 2020: -$81.32 million | Fiscal year 2019: -$43.74 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: